JP2007520566A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2007520566A5 JP2007520566A5 JP2006552302A JP2006552302A JP2007520566A5 JP 2007520566 A5 JP2007520566 A5 JP 2007520566A5 JP 2006552302 A JP2006552302 A JP 2006552302A JP 2006552302 A JP2006552302 A JP 2006552302A JP 2007520566 A5 JP2007520566 A5 JP 2007520566A5
- Authority
- JP
- Japan
- Prior art keywords
- autoantigen
- antibody
- pharmaceutical composition
- antigen
- kit
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US54195904P | 2004-02-04 | 2004-02-04 | |
| PCT/US2005/003712 WO2005076965A2 (en) | 2004-02-04 | 2005-02-04 | Anti-cd3 and antigen-specific immunotherapy to treat autoimmunity |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2007520566A JP2007520566A (ja) | 2007-07-26 |
| JP2007520566A5 true JP2007520566A5 (enExample) | 2008-03-27 |
Family
ID=34860238
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2006552302A Pending JP2007520566A (ja) | 2004-02-04 | 2005-02-04 | 自己免疫治療のための抗ｃｄ３及び抗原特異的免疫療法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20070190045A1 (enExample) |
| EP (1) | EP1725254A4 (enExample) |
| JP (1) | JP2007520566A (enExample) |
| AU (1) | AU2005213449A1 (enExample) |
| CA (1) | CA2554978A1 (enExample) |
| IL (1) | IL177193A0 (enExample) |
| WO (1) | WO2005076965A2 (enExample) |
Families Citing this family (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030108548A1 (en) * | 1993-06-01 | 2003-06-12 | Bluestone Jeffrey A. | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| AU2003300681A1 (en) * | 2002-10-02 | 2004-05-04 | Diamyd Medical Ab | Formulation of glutarmic acid decarboxylase (gad65) and serum albumin |
| CA2569509C (en) | 2004-06-03 | 2014-08-12 | Novimmune S.A. | Anti-cd3 antibodies and methods of use thereof |
| NZ560359A (en) * | 2005-02-04 | 2009-11-27 | Dow Agrosciences Llc | Anti-T cell and autoantigen treatment of autoimmune disease using CD3 monoclonal antibodies and glutamic acid decarboxylase, insulin, beta cell protein or a combination thereof. |
| CA2614640A1 (en) * | 2005-07-11 | 2007-01-18 | Macrogenics, Inc. | Methods for the treatment of autoimmune disorders using immunosuppressive monoclonal antibodies with reduced toxicity |
| EA014025B1 (ru) * | 2005-09-12 | 2010-08-30 | Новиммун С.А. | Композиции антитела против cd3 |
| US8748126B2 (en) * | 2005-11-29 | 2014-06-10 | Actogenix N.V. | Induction of mucosal tolerance to antigens |
| US20100061984A1 (en) * | 2006-01-20 | 2010-03-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for modulation of suppressor t cell activation |
| WO2007145941A2 (en) * | 2006-06-06 | 2007-12-21 | Tolerrx, Inc. | Administration of anti-cd3 antibodies in the treatment of autoimmune diseases |
| SG10201504662WA (en) * | 2006-06-14 | 2015-07-30 | Macrogenics Inc | Methods For The Treatment Of Autoimmune Disorders Using Immunosuppressive Monoclonal Antibodies With Reduced Toxicity |
| WO2008079713A2 (en) * | 2006-12-21 | 2008-07-03 | Macrogenics Inc. | Methods for the treatment of lada and other adult-onset autoimmune diabetes using immunosuppressive monoclonal antibodies with reduced toxicity |
| DE102007001370A1 (de) * | 2007-01-09 | 2008-07-10 | Curevac Gmbh | RNA-kodierte Antikörper |
| JP2010516269A (ja) | 2007-01-25 | 2010-05-20 | アクトジェニックス・エヌブイ | 抗原の粘膜送達による免疫疾患の治療 |
| MX2009011481A (es) * | 2007-04-24 | 2010-02-01 | Diamyd Therapeutics Ab | Medicamentos y metodos para tratar enfermedad autoinmune y cancer. |
| WO2011050106A2 (en) * | 2009-10-20 | 2011-04-28 | Tolerx, Inc. | Anti-cd3 antibody dosing in autoimmune disease |
| WO2011091138A1 (en) * | 2010-01-20 | 2011-07-28 | Bayhill Therapeutics, Inc. | Combination therapy to treat autoimmune diseases |
| WO2012012737A2 (en) | 2010-07-23 | 2012-01-26 | The University Of Toledo | Stable tregs and related materials and methods |
| CN103372214B (zh) * | 2012-04-13 | 2017-09-29 | 北京艾棣维欣生物技术有限公司 | 治疗和/或预防ⅰ型糖尿病的药物组合物及其应用 |
| US8735359B2 (en) * | 2012-05-24 | 2014-05-27 | Orban Biotech Llc | Combinations of modalities for the treatment of diabetes |
| SI3151853T1 (sl) * | 2014-06-04 | 2020-10-30 | Diamyd Medical Ab | Dekarboksilaza glutaminske kisline (GAD) za uporabo v zdravljenju avtoimunske bolezni |
| GB201510056D0 (en) * | 2015-06-10 | 2015-07-22 | King S College London | Multi-peptide composition |
| CA3046489A1 (en) | 2016-12-07 | 2018-06-14 | Progenity Inc. | Gastrointestinal tract detection methods, devices and systems |
| US20210138213A1 (en) | 2017-03-30 | 2021-05-13 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immune modulatory agent released using an ingestible device |
| AU2018315052B2 (en) * | 2017-08-07 | 2025-01-02 | St Vincent's Institute Of Medical Research | Type 1 diabetes therapy |
| WO2019246312A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease of the gastrointestinal tract with an immunomodulator |
| WO2019246317A1 (en) | 2018-06-20 | 2019-12-26 | Progenity, Inc. | Treatment of a disease or condition in a tissue originating from the endoderm |
| CN116726361A (zh) | 2018-11-19 | 2023-09-12 | 比奥拉治疗股份有限公司 | 用生物治疗剂治疗疾病的方法和装置 |
| IL288024B2 (en) | 2019-05-14 | 2025-12-01 | Provention Bio Inc | Methods and compositions for preventing type |
| AU2020398147A1 (en) | 2019-12-06 | 2022-06-02 | Dr. Mary Morris & Associates, Llc | Methods and compositions for the treatment and prevention of Type 1 diabetes |
| WO2021119482A1 (en) | 2019-12-13 | 2021-06-17 | Progenity, Inc. | Ingestible device for delivery of therapeutic agent to the gastrointestinal tract |
| US12006366B2 (en) | 2020-06-11 | 2024-06-11 | Provention Bio, Inc. | Methods and compositions for preventing type 1 diabetes |
| MX2023013851A (es) | 2021-05-24 | 2023-12-08 | Provention Bio Inc | Metodos para el tratamiento de diabetes tipo 1. |
| US12122850B2 (en) | 2022-03-14 | 2024-10-22 | LamKap Bio gamma AG | Bispecific GPC3xCD28 and GPC3xCD3 antibodies and their combination for targeted killing of GPC3 positive malignant cells |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6406696B1 (en) * | 1989-10-27 | 2002-06-18 | Tolerance Therapeutics, Inc. | Methods of stimulating the immune system with anti-CD3 antibodies |
| JP2546544B2 (ja) * | 1989-10-27 | 1996-10-23 | アーチ ディベラップメント コーポレイション | 免疫強化を促進するための方法と組成物 |
| US6150584A (en) * | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5770429A (en) * | 1990-08-29 | 1998-06-23 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US6491916B1 (en) * | 1994-06-01 | 2002-12-10 | Tolerance Therapeutics, Inc. | Methods and materials for modulation of the immunosuppresive activity and toxicity of monoclonal antibodies |
| US5885573A (en) * | 1993-06-01 | 1999-03-23 | Arch Development Corporation | Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies |
| FR2730411B1 (fr) * | 1995-02-14 | 1997-03-28 | Centre Nat Rech Scient | Association medicamenteuse utile pour la transfection et l'expression in vivo d'exogenes |
| US5834597A (en) * | 1996-05-20 | 1998-11-10 | Protein Design Labs, Inc. | Mutated nonactivating IgG2 domains and anti CD3 antibodies incorporating the same |
| US6420140B1 (en) * | 1996-10-11 | 2002-07-16 | Abgenix, Inc. | Production of multimeric protein by cell fusion method |
| US6884785B2 (en) * | 1999-06-17 | 2005-04-26 | The Scripps Research Institute | Compositions and methods for the treatment or prevention of autoimmune diabetes |
| US7378089B2 (en) * | 2001-10-02 | 2008-05-27 | The Board Of Trustees Of The Leland Stanford Junior University | Gene therapy for the prevention of autoimmune disease |
| US20040037826A1 (en) * | 2002-06-14 | 2004-02-26 | Michelsen Birgitte Koch | Combined use of a modulator of CD3 and a GLP-1 compound |
-
2005
- 2005-02-04 WO PCT/US2005/003712 patent/WO2005076965A2/en not_active Ceased
- 2005-02-04 JP JP2006552302A patent/JP2007520566A/ja active Pending
- 2005-02-04 AU AU2005213449A patent/AU2005213449A1/en not_active Abandoned
- 2005-02-04 EP EP05722771A patent/EP1725254A4/en not_active Withdrawn
- 2005-02-04 CA CA002554978A patent/CA2554978A1/en not_active Abandoned
-
2006
- 2006-08-01 IL IL177193A patent/IL177193A0/en unknown
- 2006-08-03 US US11/498,381 patent/US20070190045A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2007520566A5 (enExample) | ||
| JP2005518433A5 (enExample) | ||
| JP2007527914A5 (enExample) | ||
| EA201100958A1 (ru) | Фармацевтическая пероральная дозированная лекарственная форма на основе ингибиторов dpp iv | |
| IL191117A (en) | Use of an anti-40 cd antibody in the preparation of a pharmaceutical preparation for the treatment of inflammatory or autoimmune disease and a preparation prepared therefor | |
| AR057807A1 (es) | Formulaciones de anticuerpo anti-cd3 | |
| IL198870A0 (en) | ANTIBODIES THAT BIND TO HUMAN PDGFRa AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME | |
| HRP20192295T1 (hr) | Optimizirana monoklonska protutijela protiv inhibitora faktora tkivnog puta (tfpi) | |
| IL197831A (en) | Human antibodies that bind 4cxcr, preparations containing them and their uses | |
| JP2009521520A5 (enExample) | ||
| JP2007522094A5 (enExample) | ||
| IL199216A (en) | Monoclonal Antibodies Against 3angptl, Pharmaceuticals Containing Them and Their Uses | |
| JP2012509886A5 (enExample) | ||
| NO20083785L (no) | Funksjonelle antistoffer | |
| AR074777A1 (es) | Proteinas de union a antigeno | |
| IL178838A (en) | Antibodies that specifically bind to human p-psgl-1 and p-selectin, pharmacological preparations containing such antibody, and momentary acids and their encoded vectors | |
| IL209499A (en) | Human monoclonal antibody against influenza a virus, pharmaceutical compositions comprising the same and use thereof as medicaments | |
| JP2009505678A5 (enExample) | ||
| WO2009114040A3 (en) | Anti-il-12/23p40 antibodies, epitopes, formulations, compositions, methods and uses | |
| WO2018116267A3 (en) | Methods of treatment with anti-factor xi/xia antibodies | |
| JP2011528897A5 (enExample) | ||
| IL179240A (en) | Use of an antibody bound to the complement component 5c for the preparation of drugs to assess the survival of an implant, and pharmaceutical packaging and injection kits containing this antibody | |
| EA201290671A1 (ru) | Антигенсвязывающие белки, специфические в отношении сывороточного амилоидного компонента р | |
| MA37645A3 (fr) | Formulations stabilisées contenant des anticorps anti-dll4 | |
| WO2010023482A3 (en) | Therapeutic antibody |